Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria.

  title={Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria.},
  author={Christel JM. de Blok and Chantal Maria Wiepjes and Daan M. van Velzen and Annemieke S Staphorsius and Nienke M Nota and Louis J Gooren and Baudewijntje P.C. Kreukels and Martin den Heijer},
  journal={The lancet. Diabetes \& endocrinology},
BACKGROUND Increased mortality in transgender people has been described in earlier studies. Whether this increased mortality is still present over the past decades is unknown. Therefore, we aimed to investigate trends in mortality over five decades in a large cohort of adult transgender people in addition to cause-specific mortality. METHODS We did a retrospective cohort study of adult transgender people who visited the gender identity clinic of Amsterdam University Medical Centre in the… 
3 Citations
Mortality risk in transgender people is twice as high as in cisgender people, data show
The study included 2927 transgender women and 1641 transgender men who visited the gender identity clinic of Amsterdam University Medical Centre in the Netherlands and received hormone treatment from 1972 to 2018, finding that the average age at the start of hormone treatment was 30 in transgenderWomen and 23 in transgender men.
Diabetic ketoacidosis risk during the COVID-19 pandemic
Health disparities in transgender people.


The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): Trends in Prevalence, Treatment, and Regrets.
The number of people with gender identity issues seeking professional help increased dramatically in recent decades, and special attention should be given to those who choose less common forms of treatment.
A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
The increased mortality in hormone-treated MtF transsexuals was mainly due to non-hormone-related causes, but ethinyl estradiol may increase the risk of cardiovascular death, and use of testosterone in doses used for hypogonadal men seemed safe.
Mortality and morbidity in transsexual patients with cross-gender hormone treatment.
The dilemma of prescribing cross gender hormones in view of the needs of these patients is not resolved, and follow up of this relatively young population to disclose long-term side effects and to elucidate the association of sex steroids with coronary heart disease is required.
The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment
It is concluded that cross-sex hormone treatment is associated with a higher risk of meningiomas and prolactinomas in transwomen, which may be linked to cyproterone acetate usage, and somatotrophinoma in transmen.
Cancer in Transgender People: Evidence and Methodological Considerations.
The goals of this article are to summarize the evidence on factors that may differentially affect cancer risk in transgender people, assess the relevant cancer surveillance and epidemiologic data available to date, and offer an overview of possible methodological considerations for future studies investigating cancer incidence and mortality in this population.
Mortality Among Veterans with Transgender-Related Diagnoses in the Veterans Health Administration, FY2000-2009.
The crude suicide rate among veterans with transgender-related ICD-9-CM diagnoses is higher than in the general population, and they may be dying by suicide at younger ages than their veteran peers without transgender- related I CD- 9- CM diagnoses.
Incidence of breast cancer in a cohort of 5,135 transgender veterans
It appears that TG veterans do not display an increase in breast cancer incidence, consistent with European studies of longer duration that conclude that CSH treatment in gender dysphoric patients of either birth sex does not result in a greater incidence than the general population.
Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy
Cross-sex hormone therapy (CSHT), particularly with testosterone, is associated with worsening cardiovascular risk factors in transgender men but not with increases in cardiovascular morbidity or mortality, and the literature regarding the association between CSHT and CVD in transgender adults is summarized.
Prevalence of gender identity disorder and suicide risk among transgender veterans utilizing veterans health administration care.
The prevalence and incidence of gender identity disorder diagnoses among veterans in the Veterans Health Administration (VHA) health care system and suicide risk among veterans with a GID diagnosis were estimated and examined.
Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy.
Transsexual women before the start of hormonal therapy appear to have lower muscle mass and strength and lower bone mass compared with control men, which might be related to a less active lifestyle.